Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Hepatitis C

Hajira Basit  1 , Janak Koirala  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Hepatitis C

Hajira Basit et al.
Free Books & Documents

Excerpt

First diagnosed in 1989, the hepatitis C virus (HCV) is a significant public health problem affecting 58 million people worldwide. The percentage of people who are seropositive for anti-HCV antibodies worldwide is estimated to have increased from 2.3% to 2.8% between 1990 and 2005. Most patients (80% to 85%) who become acutely infected cannot clear the virus and progress to chronic infection. The effects of chronic infection include cirrhosis, portal hypertension, hepatic decompensation with encephalopathy, and hepatocellular carcinoma. HCV is the most common blood-borne pathogen and a leading cause of morbidity and mortality. The treatment landscape has evolved substantially since introducing highly active direct-acting antivirals (DAAs) in 2011. The goals of treatment aim at viral eradication, delaying fibrosis progression, alleviating symptoms, preventing complications, minimizing all-cause mortality, and ultimately maximizing the quality of life.[3]

PubMed Disclaimer

Conflict of interest statement

Disclosure: Hajira Basit declares no relevant financial relationships with ineligible companies.

Disclosure: Janak Koirala declares no relevant financial relationships with ineligible companies.

References

    1. Mashiba T, Joko K, Kurosaki M, Ochi H, Hasebe C, Akahane T, Sohda T, Tsuji K, Mitsuda A, Kimura H, Narita R, Ogawa C, Furuta K, Shigeno M, Okushin H, Ito H, Kusakabe A, Satou T, Kawanami C, Nakata R, Kobashi H, Tamada T, Ide Y, Yagisawa H, Morita A, Matsushita T, Okada K, Izumi N. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res. 2019 Oct;49(10):1114-1120. - PMC - PubMed
    1. Morales-Arraez D, Alonso-Larruga A, Diaz-Flores F, García Dopico JA, de Vera A, Quintero E, Hernández-Guerra M. Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. J Viral Hepat. 2019 Sep;26(9):1117-1123. - PubMed
    1. Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf. 2019 Jul;18(7):603-610. - PubMed
    1. Kamimura K, Sakamaki A, Kamimura H, Setsu T, Yokoo T, Takamura M, Terai S. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World J Gastroenterol. 2019 Apr 21;25(15):1817-1827. - PMC - PubMed
    1. Parigi TL, Torres MCP, Aghemo A. Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. Clin Mol Hepatol. 2019 Dec;25(4):360-365. - PMC - PubMed

Publication types

LinkOut - more resources